CN111108118A - 用C5a活性抑制剂治疗炎性疾病 - Google Patents

用C5a活性抑制剂治疗炎性疾病 Download PDF

Info

Publication number
CN111108118A
CN111108118A CN201880037003.9A CN201880037003A CN111108118A CN 111108118 A CN111108118 A CN 111108118A CN 201880037003 A CN201880037003 A CN 201880037003A CN 111108118 A CN111108118 A CN 111108118A
Authority
CN
China
Prior art keywords
antibody
antigen
binding
compound
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880037003.9A
Other languages
English (en)
Chinese (zh)
Inventor
郭仁峰
尼尔斯·C·里德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InflaRx GmbH
Original Assignee
InflaRx GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by InflaRx GmbH filed Critical InflaRx GmbH
Publication of CN111108118A publication Critical patent/CN111108118A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880037003.9A 2017-04-03 2018-01-03 用C5a活性抑制剂治疗炎性疾病 Pending CN111108118A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17164573 2017-04-03
EP17164573.2 2017-04-03
EP17177657.8 2017-06-23
EP17177657 2017-06-23
EP17189938.8 2017-09-07
EP17189938 2017-09-07
PCT/EP2018/050146 WO2018184739A1 (en) 2017-04-03 2018-01-03 Treatment of inflammatory diseases with inhibitors of c5a activity

Publications (1)

Publication Number Publication Date
CN111108118A true CN111108118A (zh) 2020-05-05

Family

ID=61024731

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880037003.9A Pending CN111108118A (zh) 2017-04-03 2018-01-03 用C5a活性抑制剂治疗炎性疾病

Country Status (17)

Country Link
US (1) US11273225B2 (https=)
EP (3) EP3411400B1 (https=)
JP (2) JP7486415B2 (https=)
KR (1) KR20190138806A (https=)
CN (1) CN111108118A (https=)
AU (1) AU2018249310A1 (https=)
CA (1) CA3058023A1 (https=)
CL (1) CL2018002698A1 (https=)
DK (1) DK3411400T3 (https=)
ES (1) ES2893769T3 (https=)
IL (1) IL261809B2 (https=)
MX (1) MX2019011825A (https=)
PL (1) PL3411400T3 (https=)
SG (1) SG11201807998WA (https=)
TW (2) TWI826364B (https=)
WO (1) WO2018184739A1 (https=)
ZA (1) ZA201906485B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201241A (zh) * 2017-06-23 2020-05-26 因弗拉克斯有限责任公司 用C5a活性抑制剂治疗炎性疾病
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
US11890349B2 (en) 2017-04-03 2024-02-06 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5A activity
US12606613B2 (en) 2020-05-06 2026-04-21 Inflarx Gmbh Humanized anti-C5a antibodies

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
SMT202400521T1 (it) 2018-11-30 2025-01-14 Chemocentryx Inc Formulazioni di capsula
EP3934675A2 (en) * 2019-03-08 2022-01-12 RA Pharmaceuticals, Inc. Zilucoplan as deep tissue penetrating c5 inhibitor
US11149009B2 (en) 2019-03-11 2021-10-19 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor
BR112021017820A2 (pt) * 2019-04-24 2022-02-08 Ra Pharmaceuticals Inc Composições e métodos para modulação da atividade de complemento
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
AU2021324314A1 (en) * 2020-08-12 2023-05-25 Innate Pharma Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab
WO2022093971A1 (en) * 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
CN116036233A (zh) * 2023-01-10 2023-05-02 中山大学附属第八医院（深圳福田） 小分子化合物pmx 53在制备抑制血管钙化和血管纤维化药物中的应用
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120231008A1 (en) * 2009-11-26 2012-09-13 Renfeng Guo Anti-C5A Binding Moieties with High Blocking Activity
WO2015140304A1 (en) * 2014-03-20 2015-09-24 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
PL3385384T3 (pl) 2004-02-12 2021-03-08 Archemix Llc Aptamerowe środki terapeutyczne użyteczne w leczeniu zaburzeń powiązanych z dopełniaczem
EP2049141A4 (en) 2006-07-21 2011-10-26 Promics Pty Ltd TREATMENT OF INTIMAL HYPERPLASIA AND ASSOCIATED DISEASES
MX2009001914A (es) * 2006-08-22 2009-03-31 G2 Inflammation Pty Ltd Anticuerpos anti-c5ar con propiedades mejoradas.
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
WO2011056972A2 (en) * 2009-11-04 2011-05-12 Case Western Reserve University Compositions and methods of treating a t cell mediated disorder
CA2965223C (en) 2008-12-22 2019-09-24 Chemocentryx, Inc. C5ar antagonists
PT2585064T (pt) 2010-06-24 2017-08-08 Chemocentryx Inc Antagonistas do c5ar
CA3216595A1 (en) 2013-03-14 2014-10-02 Kevin Fitzgerald Complement component c5 irna compositions and methods of use thereof
WO2016044419A1 (en) 2014-09-16 2016-03-24 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2016061066A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of replicating a large scale eculizumab production cell culture
FR3030515B1 (fr) * 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
EP3313437A1 (en) 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
AU2017246228B2 (en) 2016-04-04 2021-04-15 Chemocentryx, Inc. Soluble C5aR antagonists
TWI826364B (zh) * 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
US11149009B2 (en) 2019-03-11 2021-10-19 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120231008A1 (en) * 2009-11-26 2012-09-13 Renfeng Guo Anti-C5A Binding Moieties with High Blocking Activity
CN105037541A (zh) * 2009-11-26 2015-11-11 因弗拉克斯有限责任公司 具有高阻断活性的抗-C5a结合部分
WO2015140304A1 (en) * 2014-03-20 2015-09-24 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
CN106132982A (zh) * 2014-03-20 2016-11-16 因弗拉克斯有限责任公司 用于治疗病毒性肺炎的C5a抑制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EQS GROUP AG ET AL.: "InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa", pages 1 *
SHIHUI SUN等: "Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys", 《CLIN INFECT DIS》, vol. 60, no. 4, pages 586 - 595, XP055254473, DOI: 10.1093/cid/ciu887 *
武琳琳;帅宗文;: "补体活化旁路途经在抗中性粒细胞胞质抗体相关性血管炎发病机制中作用的研究进展", 中华临床医师杂志(电子版), no. 22, pages 146 - 149 *
陈忱;吕若芸;魏敬双;: "C5a在炎症反应中的作用及其抗体药物的研究进展", 《中国生物制品学杂志》, vol. 28, no. 05, pages 112 - 115 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11890349B2 (en) 2017-04-03 2024-02-06 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5A activity
CN111201241A (zh) * 2017-06-23 2020-05-26 因弗拉克斯有限责任公司 用C5a活性抑制剂治疗炎性疾病
US12606613B2 (en) 2020-05-06 2026-04-21 Inflarx Gmbh Humanized anti-C5a antibodies
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法

Also Published As

Publication number Publication date
ES2893769T3 (es) 2022-02-10
EP4272821A3 (en) 2024-01-03
DK3411400T3 (da) 2021-10-11
JP2020515643A (ja) 2020-05-28
EP3978523A1 (en) 2022-04-06
TW202348249A (zh) 2023-12-16
KR20190138806A (ko) 2019-12-16
JP2022176946A (ja) 2022-11-30
ZA201906485B (en) 2021-08-25
MX2019011825A (es) 2020-12-11
AU2018249310A1 (en) 2019-10-17
CA3058023A1 (en) 2018-10-11
WO2018184739A1 (en) 2018-10-11
US11273225B2 (en) 2022-03-15
TWI826364B (zh) 2023-12-21
US20180282425A1 (en) 2018-10-04
EP3411400A1 (en) 2018-12-12
PL3411400T3 (pl) 2021-12-20
EP3411400B1 (en) 2021-09-22
IL261809B2 (en) 2024-04-01
IL261809A (en) 2018-11-29
CL2018002698A1 (es) 2018-12-07
EP4272821A2 (en) 2023-11-08
TW201836641A (zh) 2018-10-16
IL261809B1 (en) 2023-12-01
JP7486415B2 (ja) 2024-05-17
SG11201807998WA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
CN111108118A (zh) 用C5a活性抑制剂治疗炎性疾病
US11464868B2 (en) Treatment of inflammatory diseases with inhibitors of C5A activity
TWI786132B (zh) 活性抑制劑於發炎性疾病之治療
US10961304B2 (en) Method of reducing the effect of a stroke comprising administering an inhibitor of vascular endothelial growth factor B (VEGF-B)
US12583929B2 (en) Method of treating acute respiratory distress syndrome
HK40101423A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
HK40070841A (en) Treatment of inflammatory diseases with inhibitors of c5a activity
EA043076B1 (ru) Лечение воспалительных заболеваний с помощью ингибиторов активности c5a
HK40000612B (en) Treatment of inflammatory diseases with inhibitors of c5a activity
HK1242603B (en) Method of treating or preventing stroke

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination